Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy

Area of Science:

• Nephrology
• Metabolic Syndrome Research
• Inflammation Biology

Background:

• Metabolic syndrome triggers abnormal inflammatory responses leading to kidney injury.
• Renal lipid accumulation and lipotoxicity are linked to inflammation, potentially explaining fibrosis and cellular decay in metabolic syndrome nephropathy.
• The independent protective effect of inflammation control on the kidney, separate from lipid accumulation, remains unclear.

Purpose of the Study:

• To investigate if mycophenolate mofetil (MMF) treatment reduces renal lipid accumulation, inflammation, and injury in rats with metabolic syndrome and nephropathy.
• To determine if anti-inflammatory therapy can protect the kidney independently of addressing lipid accumulation in hyperglycemia and dyslipidemia.

Main Methods:

• Obese and lean Zucker fatty diabetic/spontaneous hypertensive heart failure (ZS) rats were treated with MMF (10 mg.kg(-1).day(-1) intraperitoneally for 14 weeks).
• Evaluated MMF's effects on renal lipid depots, inflammation markers, kidney size, hyperfiltration, and fibrosis.
• Compared outcomes between lean and obese ZS rats, and between MMF-treated and untreated obese ZS rats.

Main Results:

• MMF did not significantly alter hyperglycemia or kidney lipid/peroxidation levels in obese ZS rats.
• MMF markedly decreased systemic and renal inflammation in obese ZS rats.
• MMF treatment limited kidney enlargement, hyperfiltration, and fibrosis in obese ZS rats, without affecting lean rats.

Conclusions:

• In rats with metabolic syndrome and nephropathy, MMF treatment effectively reduced renal inflammation and fibrosis.
• Anti-inflammatory therapy, acting downstream and independently of lipotoxicity, can limit kidney injury and fibrosis.
• These findings suggest a potential therapeutic strategy for metabolic syndrome-related kidney disease by targeting inflammation.